Diagnostic Health delisted from the Nasdaq:
This article was originally published in Clinica
US diagnostic services and equipment company Diagnostic Health Services has been delisted from the Nasdaq stock market. This month the Dallas, Texas-based radiology and cardiology outsourcing service company announced that the planned merger between it and Medical Alliance would not go ahead. Second-quarter revenues slipped to $11 million from last year's $15.2 million, though the company reduced its loss (before charges relating to the failed merger), to $765,000, from $2.1 million loss in the same period last year.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.